Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals. • 612-624-2620 • 1-888-226-2376

Breast cancer Clinical Trials

Protocol Number Title
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (ISPY2)
2009UC147: SURMOUNT: Surveillance Markers of Utility for Recurrence after Neoadjuvant Therapy for Breast Cancer (Supplement 3 Sub-study to ISPY2)
Vascular Assessment in Breast Cancer Survivors Taking Aromatase Inhibitors
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer.
Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant
Merrimack MM302-02-02-03: A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician?s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope)
A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Aromatase Inhibitors and Vascular Health
Mitochondrial based biomarkers for early detection of breast cancer

13 trials displayed

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on